1. Home
  2. IMRN

IMRN

Immuron Limited

Logo Immuron Limited

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Founded: 1994 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 17.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 932.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.43 EPS Growth: N/A
52 Week Low/High: $1.48 - $5.96 Next Earning Date: 04-19-2024
Revenue: $2,433,088 Revenue Growth: 903.46%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: